Arija, S. ManriqueCabezas-Lucena, A. M.Godoy-Navarrete, F.Morales-Aguila, M.Redondo, R.Mena-Vazquez, N.2023-05-032023-05-032022-06-01Arija, S. M., Cabezas-Lucena, A. M., Godoy-Navarrete, F., Morales-Águila, M., Redondo, R., & Mena-Vázquez, N. (2022). AB0753 REAL LIFE DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. UTILITY OF THE REDOSER TOOL. Annals Of The Rheumatic Diseases, 81(Suppl 1), 1502.1-15020003-4967http://hdl.handle.net/10668/20053Background: The long-term use of standard dosing of TNFi therapy is costly and not without side effects, including infections, tuberculosis and potential malignancies(1,2,). Hence, we undertook this study to determine whether dose reduction of TNFi therapy may be possible in a realworld setting and if REDOSER tool(3) is an appropriateness criteria for reducing the dose of BT. Objectives: Describe the percentage of patients with inflammatory rheumatic diseases (IRD) who continue with dose reduction of biological therapy (BT). Evaluate relapse in clinical practice after 2 years of follow-up. Identify factors associated with relapse. Methods: Retrospective observational study. Patients with axial spondyloarthritis (axial SpA), psoriatic arthritis (PSA) and rheumatoid arthritis (RA) in BT dose reduction. Inclusion criteria: Axial SpA according to ASAS criteria, APS according to CASPAR criteria and RA according to ACR2010 criteria, who have started reducing the dose of BT treatment between 2009-2019 at the Hospital Regional Universitario de Málaga, Spain. Protocol: patients with TB are followed prospectively in a monographic consultation with a pre-established protocol. The day of dose reduction = baseline visit (v0).enBritish societyArthritisRiskArthritis, PsoriaticDrug TaperingArthritis, RheumatoidAxial SpondyloarthritisBiological TherapyTuberculosisNeoplasmsconference outputRestricted AccessReducción gradual de medicamentosRecurrenciaArtritis PsoriásicaInfeccionesTerapia biológicaEnfermedades reumáticas10.1136/annrheumdis-2022-eular.4451468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/1502.1.full.pdf850279006149